<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00803270</url>
  </required_header>
  <id_info>
    <org_study_id>MIMOSA (terminated)</org_study_id>
    <nct_id>NCT00803270</nct_id>
  </id_info>
  <brief_title>Mixed Incontinence: Medical Or Surgical Approach?</brief_title>
  <acronym>MIMOSA</acronym>
  <official_title>Mixed Incontinence: Medical Or Surgical Approach?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New England Research Institutes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Maryland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Texas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The University of Texas at San Antonio</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beaumont Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Loyola University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>New England Research Institutes</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare treatment outcomes for patients with mixed urinary
      incontinence (MUI) for whom therapy is initiated with surgery to those for whom therapy is
      initiated with non-surgical treatment. Women who are bothered by symptoms of both stress and
      urge incontinence will be randomly assigned to initiate treatment with a surgical (surgery
      for stress incontinence) vs. a non-surgical (drug and behavioral therapy) approach. Follow-up
      will be a minimum of 12 Months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to compare treatment outcomes for patients with mixed urinary
      incontinence (MUI) for whom therapy is initiated with surgery to those for whom therapy is
      initiated with non-surgical treatment. Women who are bothered by symptoms of both stress and
      urge incontinence will be randomly assigned to initiate treatment with a surgical (surgery
      for stress incontinence) vs. a non-surgical (drug and behavioral therapy) approach. Follow-up
      will be a minimum of 12 Months.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Feasibility Period ended.
  </why_stopped>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Optimal Outcome of Treatment at 6 Months</measure>
    <time_frame>6 Months</time_frame>
    <description>Composite measure defined as &quot;much better&quot; or &quot;very much better&quot; on Patient Global Impression of Improvement (PGI-I) and &quot;normal&quot; or &quot;mild&quot; on Patient Global Impression of Symptoms (PGI-S). PGI-I is a single item: &quot;Circle the one answer that best describes your urinary tract condition now, compared to how it was before your incontinence treatment&quot; with responses ranging from 1= &quot;Very much better&quot; to 7= &quot;Very much worse.&quot; The PGI-S is a single item:; &quot;Circle the one number that best describes how your urinary tract condition is now&quot; with responses ranging from 1 = &quot;Normal&quot; to 4 &quot;Severe&quot;.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Optimal Outcome of Treatment at 3 Months</measure>
    <time_frame>3 months</time_frame>
    <description>Composite measure defined as &quot;much better&quot; or &quot;very much better&quot; om PGI-I and &quot;normal&quot; or &quot;mild&quot; on PGI-S. PGI-I is a single item: &quot;Circle the one answer that best describes how your urinary tract condition is now, compared with how it was before your incontinence treatment&quot; with responses ranging from 1=&quot;Very much better&quot; to 7=&quot;Very much worse.&quot; PGI-S is a single items: &quot;Circle the one number that best describes how your urinary tract condition is now&quot; with responses ranging from 1=&quot;Normal&quot; to 4=&quot;Severe.&quot;</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>Surgical Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Surgical treatment will consist of the following evidence-based stress incontinence procedures: mid-urethral slings (TVT, TOT, TVT-O), fascial slings, and Burch colposuspension.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non Surgical Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The non-surgical treatment will include two components:
Pharmacological therapy with any FDA approved overactive bladder (OAB) drug in approved doses; and
Behavioral therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Non-Surgical Intervention</intervention_name>
    <description>Both oral urge incontinence medication and behavioral treatment</description>
    <arm_group_label>Non Surgical Treatment</arm_group_label>
    <other_name>Non-Surgical Treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgical</intervention_name>
    <description>Initial surgical (stress incontinence surgery) treatment approach.</description>
    <arm_group_label>Surgical Treatment</arm_group_label>
    <other_name>Surgical Treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female

          2. Mixed UI as evidenced by stress and urge symptoms reported on MESA (either percent of
             urge-type symptoms ≥ the percent of stress-type symptoms or urge symptom score ≥7 if
             stress predominant) followed by report of &quot;moderately&quot; or &quot;greatly&quot;/&quot;quite a bit&quot;
             bothered to questions 2 and 3 of the 6-item Urinary Distress Index (UDI-6) or
             questions 16 and 17 of the 20-item Pelvic Fl;oor Distress Index (PFDI-20),
             respectively (See Appendix C)

          3. Moderate or severe UI as evidenced by the corresponding response on the Patient Global
             Impression of Severity (PGI-S)

          4. Incontinence symptoms present for at least (3) months*

          5. Bladder capacity &gt; 200cc (by any method)

          6. Urodynamic Stress Incontinence

          7. Eligible for both treatment interventions

          8. Available to start intervention within 6 weeks

          9. Negative urine dipstick (negative result = trace or less for leukocytes &amp; nitrites)

         10. Available for 12 months of follow-up and able to complete study assessments as per
             clinician judgment

         11. Signed consent form

        Exclusion Criteria:

          1. Age &lt;21 years*

          2. Currently undergoing or recommended to undergo treatment of pelvic organ prolapse

          3. Other indicated/planned concomitant surgery

          4. Pregnant or has not completed child bearing*

          5. &lt;12 months post-partum*†

          6. Active malignancy of cervix, uterus, fallopian tube(s) or ovary &gt; Stage I, or bladder
             of any Stage

          7. Current catheter use

          8. Unevaluated hematuria

          9. Participation in another trial that may influence the results of this study

               -  Patient can be rescreened after respective time interval has been met. †&quot;Partum&quot;
                  is defined as a delivery or other termination that occurs after 20 weeks
                  gestation.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ann Gormley, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Dartmouth-Hitchcock Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oakwood Hospital/Cancer Center</name>
      <address>
        <city>Dearborn</city>
        <state>Michigan</state>
        <zip>48123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Sciences Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229-3900</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.uitn.net</url>
    <description>Urinary Incontinence Treatment Network (UITN) Public Website</description>
  </link>
  <reference>
    <citation>Brubaker L, Moalli P, Richter HE, Albo M, Sirls L, Chai T, Kraus SR, Norton P, Chang D, Tennstedt SL. Challenges in designing a pragmatic clinical trial: the mixed incontinence -- medical or surgical approach (MIMOSA) trial experience. Clin Trials. 2009 Aug;6(4):355-64. doi: 10.1177/1740774509339239. Epub 2009 Jul 22.</citation>
    <PMID>19625327</PMID>
  </reference>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2008</study_first_submitted>
  <study_first_submitted_qc>December 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2008</study_first_posted>
  <results_first_submitted>March 26, 2012</results_first_submitted>
  <results_first_submitted_qc>April 12, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 11, 2012</results_first_posted>
  <last_update_submitted>May 8, 2013</last_update_submitted>
  <last_update_submitted_qc>May 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stress urinary incontinence, Mixed, Urge</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>40 women were screened, 29 met eligibility criteria and 27 were enrolled between November, 2008 and March, 2009. The trial was terminated in March 2009 due to inadequate enrollment.</recruitment_details>
      <pre_assignment_details>All enrolled participants were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Surgical Treatment</title>
          <description>Surgical treatment will consist of the following evidence-based stress incontinence procedures: mid-urethral slings (TVT, TOT, TVT-O), fascial slings, and Burch colposuspension.</description>
        </group>
        <group group_id="P2">
          <title>Non Surgical Treatment</title>
          <description>The non-surgical treatment will include two components:
Pharmacological therapy with any FDA approved overactive bladder (OAB) drug in approved doses; and
Behavioral therapy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Surgical Treatment</title>
          <description>Surgical treatment will consist of the following evidence-based stress incontinence procedures: mid-urethral slings (TVT, TOT, TVT-O), fascial slings, and Burch colposuspension.</description>
        </group>
        <group group_id="B2">
          <title>Non Surgical Treatment</title>
          <description>The non-surgical treatment will include two components:
Pharmacological therapy with any FDA approved OAB drug in approved doses; and
Behavioral therapy.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" spread="14"/>
                    <measurement group_id="B2" value="59" spread="14"/>
                    <measurement group_id="B3" value="56" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Optimal Outcome of Treatment at 6 Months</title>
        <description>Composite measure defined as &quot;much better&quot; or &quot;very much better&quot; on Patient Global Impression of Improvement (PGI-I) and &quot;normal&quot; or &quot;mild&quot; on Patient Global Impression of Symptoms (PGI-S). PGI-I is a single item: &quot;Circle the one answer that best describes your urinary tract condition now, compared to how it was before your incontinence treatment&quot; with responses ranging from 1= &quot;Very much better&quot; to 7= &quot;Very much worse.&quot; The PGI-S is a single item:; &quot;Circle the one number that best describes how your urinary tract condition is now&quot; with responses ranging from 1 = &quot;Normal&quot; to 4 &quot;Severe&quot;.</description>
        <time_frame>6 Months</time_frame>
        <population>Participants who attended 6 month follow-up visit</population>
        <group_list>
          <group group_id="O1">
            <title>Surgical Treatment</title>
            <description>Surgical treatment will consist of the following evidence-based stress incontinence procedures: mid-urethral slings (TVT, TOT, TVT-O), fascial slings, and Burch colposuspension.</description>
          </group>
          <group group_id="O2">
            <title>Non Surgical Treatment</title>
            <description>The non-surgical treatment will include two components:
Pharmacological therapy with any FDA approved OAB drug in approved doses; and
Behavioral therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Optimal Outcome of Treatment at 6 Months</title>
          <description>Composite measure defined as &quot;much better&quot; or &quot;very much better&quot; on Patient Global Impression of Improvement (PGI-I) and &quot;normal&quot; or &quot;mild&quot; on Patient Global Impression of Symptoms (PGI-S). PGI-I is a single item: &quot;Circle the one answer that best describes your urinary tract condition now, compared to how it was before your incontinence treatment&quot; with responses ranging from 1= &quot;Very much better&quot; to 7= &quot;Very much worse.&quot; The PGI-S is a single item:; &quot;Circle the one number that best describes how your urinary tract condition is now&quot; with responses ranging from 1 = &quot;Normal&quot; to 4 &quot;Severe&quot;.</description>
          <population>Participants who attended 6 month follow-up visit</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.99</p_value>
            <method>Fisher Exact</method>
            <param_type>Difference of proportions</param_type>
            <param_value>0.08</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.28</ci_lower_limit>
            <ci_upper_limit>0.44</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Optimal Outcome of Treatment at 3 Months</title>
        <description>Composite measure defined as &quot;much better&quot; or &quot;very much better&quot; om PGI-I and &quot;normal&quot; or &quot;mild&quot; on PGI-S. PGI-I is a single item: &quot;Circle the one answer that best describes how your urinary tract condition is now, compared with how it was before your incontinence treatment&quot; with responses ranging from 1=&quot;Very much better&quot; to 7=&quot;Very much worse.&quot; PGI-S is a single items: &quot;Circle the one number that best describes how your urinary tract condition is now&quot; with responses ranging from 1=&quot;Normal&quot; to 4=&quot;Severe.&quot;</description>
        <time_frame>3 months</time_frame>
        <population>Participants who attended 3 month follow-up visit</population>
        <group_list>
          <group group_id="O1">
            <title>Surgical Treatment</title>
            <description>Surgical treatment will consist of the following evidence-based stress incontinence procedures: mid-urethral slings (TVT, TOT, TVT-O), fascial slings, and Burch colposuspension.</description>
          </group>
          <group group_id="O2">
            <title>Non Surgical Treatment</title>
            <description>The non-surgical treatment will include two components:
Pharmacological therapy with any FDA approved OAB drug in approved doses; and
Behavioral therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Optimal Outcome of Treatment at 3 Months</title>
          <description>Composite measure defined as &quot;much better&quot; or &quot;very much better&quot; om PGI-I and &quot;normal&quot; or &quot;mild&quot; on PGI-S. PGI-I is a single item: &quot;Circle the one answer that best describes how your urinary tract condition is now, compared with how it was before your incontinence treatment&quot; with responses ranging from 1=&quot;Very much better&quot; to 7=&quot;Very much worse.&quot; PGI-S is a single items: &quot;Circle the one number that best describes how your urinary tract condition is now&quot; with responses ranging from 1=&quot;Normal&quot; to 4=&quot;Severe.&quot;</description>
          <population>Participants who attended 3 month follow-up visit</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.08</p_value>
            <p_value_desc>Fisher's Exact Test of equality of percent meeting optimal outcome.</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>difference of proportions</param_type>
            <param_value>0.45</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.21</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.03</ci_lower_limit>
            <ci_upper_limit>0.87</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Surgical Treatment</title>
          <description>Surgical treatment will consist of the following evidence-based stress incontinence procedures: mid-urethral slings (TVT, TOT, TVT-O), fascial slings, and Burch colposuspension.</description>
        </group>
        <group group_id="E2">
          <title>Non Surgical Treatment</title>
          <description>The non-surgical treatment will include two components:
Pharmacological therapy with any FDA approved OAB drug in approved doses; and
Behavioral therapy.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <limitations_and_caveats>Early termination leading to small numbers of participants for data analysis.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Anne M. Stoddard</name_or_title>
      <organization>New England Resesarch Institutes</organization>
      <phone>617-972-3331</phone>
      <email>astoddard@neriscience.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

